RESUMEN
OBJECTIVES: Chondroblastoma is a rare bone tumour that often affects children more than adults. The adult cranial affection is a unique presentation of the disease (less than 2%) that mandates specific management. Through this pooled-analysis, we aimed to examine this disease group and obtain reliable scientific conclusions. METHODS: The literature was searched for case-reports of cranial chondroblastoma. Afterwards, a pooled analysis was done for the selected articles. The data in question were the patient's age, gender, disease site, modalities of treatment, disease control, salvage treatment, and disease-specific survival. RESULTS: 122 case reports were retrieved from the literature. The median age at diagnosis was 38.5 years. Up to the moment, the standard of care remains complete resection. The relapse-free survival was 29.5 months, with a three-year relapse rate of 9% and disease-specific mortality of 0%. Most of the relapses were salvaged excellently with excision. The strongest predictor for relapse was the post-resection residual disease, with three-years relapse rates of 23.8% and 2.4% for positive and negative residuals, respectively. Adjuvant Radiotherapy failed to improve the relapse rates. CONCLUSION: Complete surgical excision is the standard of care. Post-surgical residual is the only adverse prognostic factor that predicts poor disease control.
Asunto(s)
Condroblastoma/cirugía , Neoplasias Craneales/cirugía , Adulto , Condroblastoma/mortalidad , Supervivencia sin Enfermedad , Femenino , Humanos , Masculino , Neoplasia Residual , Pronóstico , Neoplasias Craneales/mortalidadRESUMEN
Minor Salivary Gland tumours are rare, representing 2% of the head and neck tumours and less than 1% of hypopharyngeal cancers. The most common subtype of minor salivary gland tumours is adenoid cystic carcinoma. Although there are several case reports discussed it, there are only two reports discussing hypopharyngeal presentation in the literature, and they were treated by surgical resection. Despite that, our case report still to be unique as it presents a case of irresectable locally advanced tumour subjected to a trial of induction therapy.